Air pollution in big cities and a high smoking rate has led to China’s growing demands for respiratory treatments, and AstraZeneca is reacting by pouring about $77 million into production expansion at its Sydney, Australia, plant... Subscribe to Read More...
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |